title: Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events.
authors.affiliation: Indiana University School of Medicine, Indianapolis, Richard L. Roudebush VA Medical Center, Indianapolis, IN.
authors.forename: Margaret S
authors.initials: MS
authors.lastname: Sozio
authors.forename: Naga
authors.initials: N
authors.lastname: Chalasani